Related references
Note: Only part of the references are listed.Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation
Michael Scordo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH)
Irene Garcia-Cadenas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
Rosa Nguyen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A nearly fatal primary Epstein-Barr virus infection associated with low NK-cell counts in a patient receiving azathioprine: a case report and review of literature
Minna Honkila et al.
BMC INFECTIOUS DISEASES (2019)
Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia
Norimichi Hattori et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies
Xiao-Ning Gao et al.
ANNALS OF HEMATOLOGY (2019)
Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402)
Mahasweta Gooptu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus-specific T-cell counts
Mehul Gupta et al.
CYTOTHERAPY (2019)
Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia
Maria Queralt Salas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience
Cheng-ying Zhu et al.
ANNALS OF TRANSPLANTATION (2019)
Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT
Amelie Kinch et al.
LEUKEMIA & LYMPHOMA (2018)
Status of Natural Killer Cell Recovery in Day 21 Bone Marrow after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome
Norimichi Hattori et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
Li Liu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder
Amit Kalra et al.
CYTOTHERAPY (2018)
Post-Transplantation Lymphoproliferative Disorders in Adults
Daan Dierickx et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Proposed Chaoyang vascular classification for superior mesenteric-portal vein invasion, resection, and reconstruction in patients with pancreatic head cancer during pancreaticoduodenectomy - A retrospective cohort study
Jiqiao Zhu et al.
INTERNATIONAL JOURNAL OF SURGERY (2018)
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
Arjun Datt Law et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation
Uday Deotare et al.
BONE MARROW TRANSPLANTATION (2018)
Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy
Sara Mastaglio et al.
BLOOD ADVANCES (2018)
Frailty and the management of hematologic malignancies
Gregory A. Abel et al.
BLOOD (2018)
Continuous Immune Cell Differentiation Inferred From Single-Cell Measurements Following Allogeneic Stem Cell Transplantation
Yang Chen et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2018)
Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation
Amit Kalra et al.
CLINICAL TRANSPLANTATION (2018)
Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation
Shogo Kobayashi et al.
PEDIATRICS INTERNATIONAL (2017)
Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Societe rancaise de Greffe de Moelle Osseuse et Therapie Cellulaire and Eurocord
S. Nguyen et al.
BONE MARROW TRANSPLANTATION (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT
D. M. Burns et al.
BONE MARROW TRANSPLANTATION (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines
Jan Styczynski et al.
HAEMATOLOGICA (2016)
Post-transplant lymphoproliferative disorders
Vikas R. Dharnidharka et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Reconstitution of Natural Killer Cells in HLA-Matched HSCT after Reduced-Intensity Conditioning: Impact on Clinical Outcome
Caroline Pical-Izard et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab
I. Garcia-Cadenas et al.
BONE MARROW TRANSPLANTATION (2015)
EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases
J. Sanz et al.
BONE MARROW TRANSPLANTATION (2014)
Controlled Epstein-Barr virus reactivation after allogeneic transplantation is associated with improved survival
Sophie Auger et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation
Qifa Liu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis
Jennifer A. Kanakry et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: a Eurocord and Societe Francaise de Greffe de Moelle-Therapie Cellulaire collaborative study
P-Y Dumas et al.
BONE MARROW TRANSPLANTATION (2013)
Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients
Nishitha Reddy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation
Z. Peric et al.
LEUKEMIA (2011)
Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation
Anne H. Blaes et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell Transplantation
Simone Cesaro et al.
TRANSPLANTATION (2010)
Incidence and Dynamics of Epstein-Barr Virus Reactivation After Alemtuzumab-Based Conditioning for Allogeneic Hematopoietic Stem-Cell Transplantation
Ben Carpenter et al.
TRANSPLANTATION (2010)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation
Ola Landgren et al.
BLOOD (2009)
The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal
Cindy M. Chang et al.
VIRUS RESEARCH (2009)
Epstein-Barr virus, rapamycin, and host immune responses
Sheri M. Krams et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2008)
Medical progress: Hematopoietic stem-cell transplantation
EA Copelan
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
